- Pluristem Therapeutics (NASDAQ:PSTI) will collaborate with the U.S. Department of Defense to study its PLX-R18 cell therapy product for the treatment long-term lung injuries following exposure to mustard gas.
- The agreement is the second DoD study involving PLX-R18. The first is evaluating its use as a countermeasure for acute radiation syndrome.
- Financial terms are not disclosed.
- Shares are down 2% premarket on increased volume.